Blood Podcast

Clonal hematopoiesis in patients with telomere biology disorders, genomic alterations in extracutaneous juvenile xanthogranulomas, and the BCMA-CD3 bispecific antibody teclistamab in relapsed/refractory multiple myeloma

Dec 5, 2024
Discover how clonal hematopoiesis influences prognosis in telomere biology disorders, shedding light on cancer risks. Dive into the genetic landscape of extracutaneous juvenile xanthogranulomas, revealing key molecular drivers for treatment options. Learn about the promising clinical trials of teclistamab for those battling relapsed or refractory multiple myeloma, with an emphasis on its safety and efficacy after previous BCMA-targeted therapies. This discussion highlights the intersection of genetics and innovative treatment strategies.
Ask episode
Chapters
Transcript
Episode notes